Researchers are examining whether cannabinoid pathways could become new treatment targets for chronic kidney disease, a condition that already affects about 850 million people worldwide. The report highlights the scale of CKD, estimating that roughly 9.1% of the global population is living with the disease.
The burden of chronic kidney disease has increased steadily over the past two decades, and the trend is expected to continue. That growth is driving interest in fresh approaches that go beyond current standard medicines, especially as existing therapies do not fully solve the problem for many patients.
According to the summary, scientists are focusing on cannabinoid-related signaling pathways as a possible route to better understand how kidney damage develops and progresses. If those pathways prove important in CKD, they may offer a new set of biological targets for future drugs.
The research adds to the broader search for better chronic kidney disease treatments at a time when the global impact of CKD keeps rising. With millions of people affected and current options limited, studies exploring cannabinoid pathways may help shape the next generation of kidney disease therapies.
